30.75
price down icon5.30%   -1.7129
 
loading
Veracyte Inc stock is traded at $30.75, with a volume of 171.18K. It is down -5.30% in the last 24 hours and down -12.55% over the past month. Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$32.46
Open:
$31.8
24h Volume:
171.18K
Relative Volume:
0.21
Market Cap:
$2.45B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-41.00
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-11.36%
1M Performance:
-12.55%
6M Performance:
-0.45%
1Y Performance:
-0.71%
1-Day Range:
Value
$30.64
$32.19
1-Week Range:
Value
$30.64
$34.28
52-Week Range:
Value
$22.61
$50.71

Veracyte Inc Stock (VCYT) Company Profile

Name
Name
Veracyte Inc
Name
Phone
(650) 243-6300
Name
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
Employee
755
Name
Twitter
@veracyte
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, A, WAT

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
VCYT
Veracyte Inc
30.78 2.58B 399.58M -54.04M 40.13M -0.75
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
476.06 184.15B 44.56B 6.72B 6.29B 17.74
Diagnostics & Research icon
DHR
Danaher Corp
189.00 137.93B 24.57B 3.60B 5.26B 5.051
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
578.37 47.82B 4.30B 1.06B 1.04B 13.08
Diagnostics & Research icon
A
Agilent Technologies Inc
111.95 32.62B 7.07B 1.29B 993.00M 4.5355
Diagnostics & Research icon
WAT
Waters Corp
288.17 29.19B 3.17B 642.63M 516.49M 10.77

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-25 Resumed Morgan Stanley Underweight
Oct-20-25 Initiated Canaccord Genuity Hold
Mar-20-25 Initiated Craig Hallum Buy
Dec-05-24 Downgrade Goldman Buy → Neutral
Nov-15-24 Initiated Wolfe Research Outperform
Oct-16-24 Initiated UBS Buy
Oct-10-24 Initiated Guggenheim Buy
Feb-23-24 Reiterated Needham Buy
Jan-18-23 Downgrade Raymond James Outperform → Mkt Perform
Jan-05-23 Initiated Scotiabank Sector Outperform
Jan-07-22 Initiated Stephens Overweight
Nov-18-21 Resumed Goldman Buy
Jun-15-21 Initiated Raymond James Outperform
Feb-18-21 Resumed Needham Buy
Jan-28-21 Initiated Truist Buy
Nov-10-20 Initiated KeyBanc Capital Markets Sector Weight
Sep-09-20 Initiated Morgan Stanley Underweight
Jul-31-19 Initiated Lake Street Buy
Jul-02-19 Initiated Needham Buy
Nov-29-18 Downgrade Janney Buy → Neutral
Oct-31-18 Upgrade Janney Neutral → Buy
Nov-07-17 Downgrade Janney Buy → Neutral
Nov-07-17 Downgrade Piper Jaffray Overweight → Neutral
Aug-31-17 Resumed BTIG Research Buy
Nov-14-16 Resumed Leerink Partners Outperform
Dec-18-15 Initiated Cantor Fitzgerald Buy
Jun-11-15 Reiterated Leerink Partners Outperform
Nov-26-13 Initiated William Blair Outperform
View All

Veracyte Inc Stock (VCYT) Latest News

pulisher
05:49 AM

Veracyte, Inc. $VCYT Stock Holdings Lifted by First Trust Advisors LP - MarketBeat

05:49 AM
pulisher
Mar 10, 2026

Veracyte CFO Chambers sells $662k in VCYT stock - Investing.com Nigeria

Mar 10, 2026
pulisher
Mar 09, 2026

Panic Selling: Can Veracyte Inc. ride the EV waveWeekly Trade Analysis & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn

Mar 09, 2026
pulisher
Mar 09, 2026

Veracyte at Leerink Global Healthcare: Strategic Growth Focus By Investing.com - Investing.com Canada

Mar 09, 2026
pulisher
Mar 08, 2026

Are Veracyte's (VCYT) Strong 2025 Profits and Reaffirmed 2026 Outlook Redefining Its Growth Story? - simplywall.st

Mar 08, 2026
pulisher
Mar 06, 2026

Insider Sell: Rebecca Chambers Sells Shares of Veracyte Inc (VCY - GuruFocus

Mar 06, 2026
pulisher
Mar 06, 2026

Veracyte (NASDAQ:VCYT) Insider Sells 5,260 Shares - MarketBeat

Mar 06, 2026
pulisher
Mar 06, 2026

VCYT: Morgan Stanley Lowers Price Target Amidst Underweight Rati - GuruFocus

Mar 06, 2026
pulisher
Mar 06, 2026

Morgan Stanley Lowers Price Target on Veracyte to $37 From $48, Keeps Underweight Rating - marketscreener.com

Mar 06, 2026
pulisher
Mar 05, 2026

Morgan Stanley cuts Veracyte stock price target on valuation methodology By Investing.com - Investing.com Canada

Mar 05, 2026
pulisher
Mar 05, 2026

Morgan Stanley cuts Veracyte stock price target on valuation methodology - Investing.com

Mar 05, 2026
pulisher
Mar 05, 2026

Veracyte, Inc. $VCYT Shares Sold by GW&K Investment Management LLC - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

Veracyte, Inc. $VCYT Shares Acquired by ARK Investment Management LLC - MarketBeat

Mar 05, 2026
pulisher
Mar 04, 2026

Affiliate to sell 6,658 Restricted Stock Units — VCYT (NASDAQ: VCYT) - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

[144] VERACYTE, INC. SEC Filing - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Marc Stapley (NASDAQ: VCYT) reports sale of 15,000 shares for $1.92M - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Veracyte (NASDAQ: VCYT) VP has 3,006 shares withheld for taxes - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Veracyte (VCYT) CFO reports 7,234-share tax withholding, not a sale - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

[Form 4] VERACYTE, INC. Insider Trading Activity - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Veracyte (VCYT) exec sells 13,425 shares, 117,346 remain - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Veracyte (VCYT) CEO has 19,455 shares withheld to cover taxes - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Segall Bryant & Hamill LLC Has $18.31 Million Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

Champlain Investment Partners LLC Makes New $40.06 Million Investment in Veracyte, Inc. $VCYT - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

VCYT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Veracyte, Inc. (VCYT) Stock Analysis: Uncovering A Promising 34.96% Upside For Investors - DirectorsTalk Interviews

Mar 03, 2026
pulisher
Mar 03, 2026

William Blair Investment Management LLC Buys New Stake in Veracyte, Inc. $VCYT - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook - Yahoo Finance

Mar 03, 2026
pulisher
Mar 03, 2026

JPMorgan Chase & Co. Has $17.81 Million Position in Veracyte, Inc. $VCYT - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire

Mar 03, 2026
pulisher
Mar 02, 2026

Cathie Wood’s ARK sells Veracyte stock, buys MercadoLibre - Investing.com South Africa

Mar 02, 2026
pulisher
Mar 02, 2026

Cathie Wood’s ARK sells Veracyte stock, buys MercadoLibre By Investing.com - Investing.com Nigeria

Mar 02, 2026
pulisher
Mar 02, 2026

Veracyte Inc. Signals Durable Growth in Earnings Call - TipRanks

Mar 02, 2026
pulisher
Mar 02, 2026

Veracyte, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:VCYT) 2026-03-02 - Seeking Alpha

Mar 02, 2026
pulisher
Mar 02, 2026

Veracyte (VCYT) CCO John Leite receives PSU shares, withholds stock for taxes - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Veracyte (VCYT) CEO reports PSU vesting and tax withholding share disposition - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Veracyte (VCYT) CFO granted shares as PSUs vest, with tax shares withheld - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Veracyte (NASDAQ: VCYT) officer gets PSU vesting, withholds shares - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Veracyte (VCYT) SVP awarded 50,999 shares; some withheld for taxes - Stock Titan

Mar 02, 2026
pulisher
Mar 01, 2026

How Veracyte’s Profit Jump and 2026 Outlook Will Impact Veracyte (VCYT) Investors - simplywall.st

Mar 01, 2026
pulisher
Feb 28, 2026

Vanguard Group Inc. Raises Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat

Feb 28, 2026
pulisher
Feb 28, 2026

Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 28, 2026
pulisher
Feb 27, 2026

Veracyte Stock Soars 8.48%, Hits Intraday High of $39.89 - Markets Mojo

Feb 27, 2026
pulisher
Feb 27, 2026

Veracyte (VCYT) Margin Expansion To 12.8% Tests Bullish Profitability Narratives - simplywall.st

Feb 27, 2026
pulisher
Feb 27, 2026

Veracyte, Inc. (NASDAQ:VCYT) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 27, 2026
pulisher
Feb 27, 2026

Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus

Feb 27, 2026
pulisher
Feb 27, 2026

Artisan Partners Limited Partnership Acquires 1,048,692 Shares of Veracyte, Inc. $VCYT - MarketBeat

Feb 27, 2026
pulisher
Feb 26, 2026

VCYT Gains Analyst Support: Needham Raises Price Target | VCYT S - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

Veracyte Presents 15 Studies on Decipher Cancer Tests at ASCO GU Symposium - Clinical Lab Products

Feb 26, 2026
pulisher
Feb 26, 2026

Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises - Yahoo Finance

Feb 26, 2026
pulisher
Feb 26, 2026

Veracyte (NASDAQ:VCYT) Shares Gap Up on Analyst Upgrade - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Veracyte (NASDAQ:VCYT) Price Target Raised to $48.00 - MarketBeat

Feb 26, 2026

Veracyte Inc Stock (VCYT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Veracyte Inc Stock (VCYT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Stapley Marc
Chief Executive Officer
Mar 04 '26
Sale
35.97
45,523
1,637,594
357,554
Leite John
Chief Commercial Officer-CLIA
Mar 04 '26
Sale
35.19
5,260
185,083
107,580
McGuire Annie
SVP, General Counsel
Mar 04 '26
Sale
35.55
6,658
236,725
94,706
diagnostics_research DGX
$201.17
price up icon 0.51%
diagnostics_research LH
$268.76
price down icon 0.24%
diagnostics_research MTD
$1,179.82
price down icon 3.66%
$193.28
price down icon 1.85%
diagnostics_research IQV
$166.56
price down icon 2.91%
diagnostics_research WAT
$287.25
price down icon 3.31%
Cap:     |  Volume (24h):